Related Experiment Video
Updated: Jun 13, 2025
05:23
Visualization of SARS-CoV-2 using Immuno RNA-Fluorescence In Situ Hybridization
Published on: December 23, 2020
6.0K
Angiotensin-Converting Enzyme-2 (ACE2) Downregulation During Coronavirus Infection
Nurshamimi Nor Rashid1, Lina Amrani2, Abdullah Alwan3
1Department of Molecular Medicine, Faculty of Medicine, Universiti Malaya, 50603, Kuala Lumpur, Malaysia.
Molecular Biotechnology
|September 12, 2024
Summary
Coronaviruses, including SARS-CoV-2, downregulate Angiotensin-converting enzyme-2 (ACE2), a key protective enzyme. This decline exacerbates organ injury by increasing Angiotensin-II (Ang II) levels, highlighting the need to understand ACE2 mechanisms during infection.
Area of Science:
- Biochemistry
- Virology
- Pathophysiology
Background:
- Angiotensin-converting enzyme-2 (ACE2) deficiency is linked to severe outcomes in conditions like hypertension and diabetes.
- Human coronaviruses (HCoV-NL63, SARS-CoV-1, SARS-CoV-2) utilize ACE2 as a cellular receptor for entry.
- Viral binding to ACE2 triggers its downregulation via unknown mechanisms, disrupting its protective functions.
Purpose of the Study:
- To review the physiological impact of ACE2 downregulation during coronavirus infections.
- To explore the link between ACE2 decline and increased virus pathogenicity.
- To elucidate the mechanisms of ACE2 downregulation and discuss potential therapeutic strategies.
Main Methods:
- Literature review focusing on ACE2 function, coronavirus-ACE2 interactions, and molecular mechanisms.
- Analysis of existing studies on ACE2 downregulation in viral infections.
- Synthesis of data regarding the pathophysiological consequences of ACE2 loss.
Main Results:
- ACE2 downregulation disrupts the renin-angiotensin system balance, favoring Angiotensin-II (Ang II) accumulation.
- Elevated Ang II activates the Angiotensin II type 1 receptor (AT1R), promoting inflammation and organ damage.
- The precise mechanisms driving ACE2 downregulation by coronaviruses remain to be fully defined.
Conclusions:
- ACE2 downregulation is a critical factor in coronavirus-induced organ injury.
- Understanding ACE2's role is crucial for developing effective antiviral therapies.
- Further research is urgently needed to clarify ACE2 degradation pathways and therapeutic targets.
Related Concept Videos
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
500
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
500
01:25Antihypertensive Drugs: Direct Renin Inhibitors
510
The renin-angiotensin-aldosterone system (RAAS) is an intricate physiological pathway involving numerous enzymes and hormones, including renin, angiotensin-converting enzyme (ACE), angiotensin I and II, and aldosterone. Imbalances within this system increase the production of angiotensin II and aldosterone. Increased angiotensin II levels promote vasoconstriction and blood pressure elevation. Concurrently, higher aldosterone levels stimulate sodium and water reabsorption in the kidneys,...
510
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
606
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
606
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
398
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
398
01:33Hormonal Regulation
33.0K
The renin-aldosterone system is an endocrine system which guides the renal absorption of water and electrolytes, thus managing blood pressure and osmoregulation. Activation of the system begins in the kidneys with a small cluster of cells adjacent to the afferent and efferent blood vessels of the renal corpuscle. As the nephrons are filtering blood, juxtaglomerular cells monitor blood pressure. If they detect a decrease in pressure, they release the hormone renin into the bloodstream.
33.0K
01:17Antihypertensive Drugs: Action of β1 Blockers
320
β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this,...
320